OCS-05 is under clinical development by Oculis and currently in Phase I for Neuromyelitis Optica (Devic’s Syndrome). According to GlobalData, Phase I drugs for Neuromyelitis Optica (Devic’s Syndrome) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OCS-05’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OCS-05 is under development for the treatment of multiple sclerosis, optic neuritis and neuromyelitis optica (Devic’s Syndrome), glaucoma. It is a new chemical entity. It is administered through topical, oral, intravenous and subcutaneous routes. The therapeutic candidate targets intracellular serine/threonine kinase SGK-2. It was also under development for the treatment of glaucoma, amyotrophic lateral sclerosis (ALS), Parkinson disease, Alzheimer's disease (AD), major depressive disorder, diabetic retinopathy and Macular Degeneration.
Oculis operates as a clinical-stage biopharmaceutical company that offers topical treatments for acute, chronic back and front-of-the-eye ophthalmic diseases. Its pipeline product portfolio includes OCS-01 a topical treatment for diabetic macular edema, inflammation and pain, and cystoid macular edema; OCS-02 for uveitis and dry eye; OCS-05 for treating acute optic neuritis, glaucoma, and neurotrophic keratitis. Its Optireach helps in solubilizing technology to improve the ability to formulate drugs as eye drops and their bioavailability in the eye tissues including anterior and posterior segments. The company has research operations in Reykjavik, Iceland. Oculis is headquartered in Lausanne, Waadt, Switzerland.
For a complete picture of OCS-05’s drug-specific PTSR and LoA scores, buy the report here.